Abstract BCR:: ABL1-negative myeloproliferative neoplasms (MPNs) are clonal diseases
originating from a single hematopoietic stem cell that cause excessive production of mature …

Polycythemia vera (PV) is a hematopoietic stem cell neoplasm defined by activating somatic
mutations in the JAK2 gene and characterized clinically by overproduction of red blood cells …

Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera
(PV) but can diminish the mutant JAK2V617F allele burden [1, 2, 3]. After discontinuing long …

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders
characterized by activated Janus kinase (JAK)–signal transducer and activator of …

The developmental history of blood cancer begins with mutation acquisition and the
resulting malignant clone expansion. The two most prevalent driver mutations found in …

Polycythemia vera (PV) belongs to the BCR-ABL1–negative myeloproliferative neoplasms
and is characterized by activating mutations in JAK2 and clinically presents with …

Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress
has been made in better understanding the molecular pathogenesis and which patients may …

Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem
cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often …

Progression to aggressive secondary acute myeloid leukaemia (sAML) poses a significant
challenge in the management of myeloproliferative neoplasms (MPNs). Since the …

Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET)
form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven …